secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001558370-25-002541
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech subsidiary Checkpoint to be acquired by Sun Pharma for $4.10/share plus CVR
--------------------------------------------------------------------------------

- Sun Pharma to acquire Checkpoint at $4.10 per share in cash plus non-tradable CVR for up to $0.70 based on EU regulatory milestones for cosibelimab.
- Fortress, owning ~11.2% of Checkpoint shares and controlling majority voting power, agrees to vote in favor and forgo certain payments.
- Fortress will receive a 2.5% royalty on worldwide net sales of certain Checkpoint/Sun Pharma products post-closing.
- Deal expected to close by Sept 5, 2025, subject to stockholder and antitrust approvals; termination fee of $12.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000155837025002541/0001558370-25-002541-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000155837025002541/fbio-20250309x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-002541

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer